Stat3 Contributes to Resistance Toward BCR-ABL Inhibitors in a Bone Marrow Microenvironment Model of Drug Resistance

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-08-0314
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

BCR-ABL Truncation Due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

Acta Haematologica
MedicineHematology
2009English

The Secretome Engages STAT3 to Favor a Cytokine-Rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2013English

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Galectin-3 Mediates Bone Marrow Microenvironment-Induced Drug Resistance in Acute Leukemia Cells via WNT/Β-Catenin Signaling Pathway

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2015English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy